in the Surveillance, Epidemiology, and End Results program registries were examined. Differences in receipt of thyroidectomy, radiotherapy, and lymph node examination were examined by race/ethnicity. Survival also was examined by race/ethnicity. RESULTS: Nearly 70% of patients were non-Hispanic white, and 55.4% of patients received treatment. Tumor size (P 5.13), lymph node involvement (P 5.60), and residence in high poverty neighborhoods (P 5.08) did not vary by race/ethnicity. Nonwhite patients were more likely to receive no treatment (adjusted odds ratio, 0.29; 95% confidence interval [95% CI], 0.16-0.54). When receipt of radiotherapy was adjusted for, nonwhite patients had a higher risk of overall death (adjusted hazards ratio [aHR], 1.24; 95% CI, 1.01-1.54), although not disease-specific death (aHR, 1.14; 95% CI, 0.92-1.42). Patients living in areas of high poverty had lower overall survival (aHR, 1.54; 95% CI, 1.09-2.18) and disease-specific survival (aHR, 1.68; 95% CI, 1.19-2.36). CONCLUSIONS: In this population-based study of patients with ATC, nonwhite patients were found to be less likely to receive treatment. Furthermore, nonwhite patients had poorer overall survival, and patients living in areas of high poverty had both worse overall and disease-specific survival. Racial/ethnic and socioeconomic disparities appear to exist in the treatment and survival of patients with ATC. Cancer 2018;124:1780-90.
INTRODUCTION

Anaplastic thyroid cancer (ATC) accounts for approximately 1.6% of thyroid cancer cases in the United
States, yet has a 10-year overall survival (OS) rate of 14%, 1 rendering it the rarest yet most lethal form of thyroid cancer. All patients with ATC are considered to have late-stage disease regardless of tumor size and lymph node involvement. 2 Although surgery and radiotherapy (RT) have improved locoregional control in a minority of patients, OS has not significantly improved over time because the majority of cases of ATC rapidly progress to distant metastases. 3 The median survival time is 5 months, 3 which is higher among patients with resectable tumors and tumors without associated lymphatic invasion. 4 Additional identified prognostic factors include younger age (<60 years), female sex, intrathyroidal tumor, and multimodality treatment, which are associated with lower disease-specific mortality. 5 The treatment of ATC depends on the tumor stage at the time of presentation. According to the American Thyroid Association, patients who present with stage IVA or IVB resectable disease should be offered surgical resection if an R0 (no residual tumor) or R1 (microscopic residual tumor) surgical resection is possible. Surgery should be followed closely by chemotherapy and RT, within 1 to 2 weeks. 6 Rao et al recently presented findings from a single-institution retrospective review of 54 patients with ATC and reported that patients who receive trimodality therapy have improved survival. 7 Furthermore, the dose of RT appears to have an effect on survival among patients with unresectable ATC, as described in a study by Pezzi et al, 8 in which high-dose (60-75 grays) RT was found to be significantly associated with improved OS when compared with low-dose (45-59.9 grays) RT, although the median survival was 2.27 6 0.102 months in both groups.
Previous studies have reported that low socioeconomic status (SES) may be associated with the development of ATC. 9, 10 For example, in a case-controlled study comparing patients with a goiter with those with ATC matched by age, sex, and place of residence, patients with ATC were found to have lower levels of education compared with controls. 11 However, to our knowledge, the association between the effects of SES and survival has not been well described to date, and the impact of race/ethnicity on survival also has not been previously described.
The objective of the current study was to determine the effect that SES and race/ethnicity have on treatment and survival outcomes in patients with ATC. We hypothesized that among patients with ATC, treatment and survival are influenced by SES and race/ethnicity.
MATERIALS AND METHODS
Study Population
Data from 18 population-based Surveillance, Epidemiology, and End Results (SEER) program registries, which cover approximately 28% of the US population, were used in this study. The 18 SEER regions included Alaska natives; metropolitan Atlanta, Georgia; California (excluding San Francisco and Los Angeles); Connecticut; Detroit, Michigan; greater Georgia; Hawaii; Iowa; Kentucky; Los Angeles, California; Louisiana; New Jersey; New Mexico; rural Georgia; San Francisco and Oakland, California; metropolitan San Jose and metropolitan Monterey, California; Seattle, Washington; and Utah. The SEER database is publicly available and therefore the institutional review board of Emory University waived approval for the current study. All patient data within the SEER database are deidentified. A total of 760 adults (aged 18 years) who were diagnosed with their first primary malignant ATC between January 1, 1998 and December 31, 2011 were selected from the SEER database. Only patients diagnosed after 1998 were selected based on the availability of data regarding primary treatment and lymph node dissection. ATCs were included using codes 8020 to 8035 based on the International Agency for Cancer Research classification. Cases that were missing data regarding race/ethnicity (2 cases) were excluded, as were cases missing data regarding surgery (2 cases), RT (21 cases), and lymph node dissection (16 cases). The total analytic cohort contained 719 patients with ATC. Information regarding chemotherapeutic agents or targeted systemic therapy was not included in the SEER database and therefore the impact of these agents cannot be ascertained in the current study. Information regarding distant metastasis was collected in the SEER database starting in 2004, and rates of distant metastasis for those patients included from 2004 onward were included in the descriptive analysis.
Outcome Measures
The primary outcome of the current study was initial primary treatment for ATC, which included surgery, RT, and lymph node dissection. We also studied rates of RT versus no treatment. Our secondary outcome was OS and disease-specific survival (DSS) of patients with ATC.
Predictor Variables
Race/ethnicity was classified as non-Hispanic white and nonwhite. Hispanic, black, Asian/Pacific Islander, American Indian, Alaska Native, and Other Specified were included in the nonwhite category due to the small sample size of these patients. Other demographic information included age as a continuous variable and sex. Countylevel SES was determined by the 2000 US Census, in which high poverty was 15% of adults whose incomes were below the federal poverty level. Educational attainment, also measured at the county level as determined by the 2000 US Census, was divided into 3 groups: <15% with no high school education, 15% to 24.9% with no high school education, and 25% with no high school education. Time was divided into 3 periods: 1998 to 2002, 2003 to 2007, and 2008 to 2011. Marital status was defined as married, single, widowed, or separated. Clinical characteristics, including tumor size (<4 cm and 4 cm) and lymph node spread (localized, regional, and distant), were considered.
Statistical Analysis
Analyses were performed with SAS statistical software (version 9.2; SAS Institute Inc, Cary, North Carolina). Chi-square test statistics were calculated to determine the relationship between race and categorical covariates (a 5 .05). Variations in continuous variables (such as age) by race/ethnicity were determined with Student's t-tests and F-tests. Adjusted logistic models were used to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) were used to assess case characteristics associated with treatment. We adjusted for relevant sociodemographic and clinical factors that have been shown to be associated with survival, 12 and included age at diagnosis (in years), sex (male vs female), marital status (married, single, divorced/separated, widowed, or missing data), race/ethnicity (nonwhite vs non-Hispanic white), year of diagnosis (1998-2002, 2003-2007, or 2008-2011) , RT (yes vs no), tumor size (<4 cm, 4 cm, or missing data), lymph node spread (no lymph nodes, regional lymph nodes, distant lymph nodes, or missing data), no high school diploma within the county by percentage (<15%, 15%-24.9%, or 25%), and living in a county with 15% poverty (yes vs no). Treatment was examined with 2 models: the first model examined receipt of any treatment versus no treatment, and the second model compared the receipt of RT versus no RT. Kaplan-Meier survival curves were used to calculate unadjusted cumulative 5-year DSS and OS estimates. The log-rank test was used to determine statistical significance. Adjusted Cox proportional hazards models were used to estimate 5-year DSS and 5-year OS hazard ratios (HRs) and 95% CIs. For the Cox proportional hazards models, we tested significance of the proportional hazards assumptions using time and covariate interaction terms. Due to collinearity between any treatment and receipt of RT, we conducted 2 sets of Cox proportional hazards models, one of which included any treatment as a predictor and the other including RT as a predictor.
Only cases with complete information regarding all included covariates were analyzed in the model.
RESULTS
Patient Characteristics
A total of 719 patients were included in the analysis (Table 1) . A majority of patients were non-Hispanic white (500 patients [69.5%]), and 219 (30.4%) were nonwhite. The mean age at diagnosis was 67.9 years (standard deviation, 12.5 years). The majority of patients were female (440 patients [61.2%]; P < .05) and married (402 Table 2 ). We also found that female patients (P 5 .02) were more likely to receive treatment. Treatment was not shown to vary by marital status (P 5 .09). Receipt of treatment varied by education, although this was borderline statistically significant (P 5 .05), and treatment did not appear to vary by poverty level (P 5 .08) ( Table 2) . In a subset analysis of patients who underwent surgical treatment (398 patients) for ATC, the most frequent treatment combination was total thyroidectomy, lymph node examination, and RT (83 patients [20.9%]), followed by total thyroidectomy plus RT without lymph node dissection (73 patients [18.3%] ). The least frequent combination of treatment in surgical patients was subtotal thyroidectomy plus lymph node sampling without RT (11 patients [2.8%]).
In adjusted logistic regression analyses (Table 3) , race/ ethnicity was found to be predictive of treatment versus no treatment (adjusted odds ratio [aOR], 0.29; 95% confidence interval [95% CI], 0.16-0.54): nonwhite patients were nearly 70% less likely to receive any treatment when compared with non-Hispanic white patients. Advanced age (aOR, 0.96; 95% CI, 0.94-0.99) also was shown to be predictive of treatment, although the effect of age on treatment may be limited due to the 95% CI approaching 1. Factors that predicted receipt of RT versus no RT were nonwhite race/ethnicity (aOR, 0.55; 95% CI, 0.35-0.88), advanced age (aOR, 0.97; 95% CI, 0.95-0.99), and high poverty level (aOR, 0.47; 95% CI, 0.23-0.99), such that nonwhite patients and patients living in poorer counties were approximately one-half as likely to receive RT.
Survival
Kaplan-Meier analyses
In analyzing OS by race, the Kaplan-Meier curve demonstrated that nonwhite patients had a lower OS at 20 months (15.5%) compared with non-Hispanic white patients (20.8%); however, rates converged by 60 months. The 5-year DSS rate was similar for nonwhite patients (13%) and non-Hispanic white patients (11%) (P 5 .11). The 5-year OS rate, when analyzed by receipt of any treatment, was higher in patients who received any form of treatment (10.9% vs 2.1%), as was the 5-year DSS rate (12.9% vs 3.7%), both of which were found to be statistically significant (P < .0001 and P < .0001, respectively). Furthermore, receipt of RT was significantly associated with survival: the 5-year OS rate (12.0% vs 5.2%) and 5-year DSS rate (13.2% vs 8.2%) were higher in patients who received RT (P < .0001 and P < .0001, respectively) (Fig. 1) .
Multivariable Cox proportional hazards regression
In multivariable analyses of 5-year OS including RT as a predictor ( 95% CI, 0.92-1.5) ( There was no significant association noted between race/ ethnicity and 5-year DSS in models accounting for RT (Table 5 ).
In multivariable analysis of survival with receipt of any treatment as a predictor, the 5-year OS (aHR, 0.31; 95% CI, 0.24-0.41) and DSS (aHR, 0.31; 95% CI, 0.24-0.43) rates were notably lower in patients who did not receive treatment (P < .0001 and P<.0001, respectively) (Tables 4 and 5) There was no difference noted with regard to race/ethnicity in OS (aHR, 1.14; 95% CI, 0.92-1.4) or cause-specific survival (aHR, 1.07; 95% CI, 0.85-1.35). High poverty (aHR, 1.50; 95% CI, 1.05-2.16) was associated with an increased risk of cancer-related death, whereas receipt of any treatment (aHR, 0.32; 95% CI, 0.24-0.43) and marital status (aHR, 0.75; 95% CI, 0.61-0.93) were associated with a decreased risk of death. OS was similarly found to be negatively influenced by high poverty (aHR, 1.68; 95% CI, 1.19-2.36) and positively influenced by receipt of treatment (aHR, 0.31; 95% CI, 0.24-0.41) and marital status (aHR, 0.77; 95% CI, 0.62-0.94). Abbreviations: 95% CI, 95% confidence interval; aHR, adjusted hazards ratio; ATC, anaplastic thyroid cancer; NA, not applicable; OS, overall survival; RT, radiotherapy; SEER, Surveillance, Epidemiology, and End Results. a The model was adjusted for age, sex, marital status, race/ethnicity, year of diagnosis, tumor size, lymph node spread, county poverty level, and radiotherapy. b The model was adjusted for age, sex, marital status, race/ethnicity, year of diagnosis, tumor size, lymph node spread, county poverty level, and any treatment.
DISCUSSION
The results of the current population-based cohort study of patients with ATC, which to the best of our knowledge is the largest of its kind, demonstrate that nonclinical factors, specifically nonwhite race, high poverty, and lack of a high school education, are independently associated with treatment and OS, but not cause-specific survival, tumor size, or lymph node involvement. We found that race/ethnicity was associated with receipt of any treatment and, independently, also RT, although it was not associated with lymph node examination in patients who received surgical treatment. Other factors found to be associated with whether any treatment was received included lymph node involvement, sex, and educational level. According to the National Comprehensive Cancer Network (NCCN), the management of ATC involves consultation with a multidisciplinary team and establishing goals of therapy with a discussion of prognosis, risks, benefits, and palliative care options. If treatment is pursued, RT plays a central role and is recommended for patients with all stages of disease (stage IVA, stage IVB, and stage IVC). 13 In our analysis of types of treatment, RT alone was the most common treatment, followed by no treatment, followed by total thyroidectomy, lymph node examination, plus RT, all of which are modalities supported by NCCN guidelines.
We found that after adjusting for sex, tumor size, year of diagnosis, marital status, and poverty status, nonwhite patients were less likely to receive treatment, a finding that to our knowledge has not been described in the existing ATC literature. We also found that nonwhite patients were independently less likely to receive RT. In addition, patients living in neighborhoods with a high poverty rate also were less likely to receive RT. The impact of racial and economic disparities on outcomes in patients with cancer has been described extensively in patients with cancer in general, 14 and specifically breast cancer, 15, 16 lung cancer, 17 colon cancer, 11, 18 retinoblastoma, 19 and hematologic malignancies. 20 However, to the best of our knowledge, racial and economic disparities have not been previously described in the literature for patients with ATC. Several contributing factors to explain these socioeconomic and racial disparities include difficulty accessing health care providers and facilities, 21 and therefore access to cancer screening programs 22 ; insurance status 23 ; tumor biology 24 ; tumor stage at presentation 11 ; and treatment differences. 25 Treatment disparities have been described in lowincome patients diagnosed with head and neck cancer, which has been shown to contribute to survival. 26 A patient's decision to pursue treatment is multifactorial and may be influenced by their social support system, belief system, religion, and finances, to name a few. It also likely is related to their rapport with their physician as well as the physician's own biases. Although efforts to address socioeconomic disparities regarding access to care currently are underway and occur at a national policy level, 27 treatment decisions often occur in a clinic or hospital setting between patients and physicians. Understanding the factors that influence this decision, such as unconscious bias, ultimately may lead to improved outcomes. Unconscious bias, as described in the cognitive neuroscience literature, is the concept that beliefs and attitudes are shaped by automatic, unconscious, cognitive processes. Burgess et al 28 described the impact that unconscious bias has on medical decisions, and pointed to physicians' occasional discriminatory behavior despite egalitarian attitudes. External forces such as time, pressure, and fatigue may influence physicians' decisionmaking process such that unconscious stereotype-based beliefs may dominate rather than conscious, egalitarian thought. These unconscious beliefs then may influence a patient's behavior and treatment decision. 28 Introducing the concept of unconscious bias and strategies to mitigate its effects in medical education can provide awareness for physicians-in-training. Teal et al have described educational interventions to address unconscious bias, such as patient panels, using cross-cultural cases in standardized patient modules, and mindfulness training. 29 By recognizing the role that unconscious bias may play in medical decision making, physicians can make efforts to minimize the role that race/ethnicity, educational level, and SES have in treating patients and provide all patients with the treatment options that best suit the type and stage of cancer, according to NCCN guidelines.
There has been recent promise in detecting molecular markers and initiating targeted systemic therapy for patients with advanced ATC. Subbiah et al recently presented their findings regarding the efficacy of combined dabrafenib and trametinib in patients with BRAFV600-E-mutated ATC. 30 Although only approximately 25% of ATCs contain BRAF mutations, the researchers reported a 69% overall response rate, with progression-free survival and OS rates at 1 year of 79% and 80%, respectively. Patients with poor access to care may not be offered genetic testing and therefore do not benefit from these advances. Clinicians should be aware of these novel options and offer them to appropriate patients regardless of SES.
We acknowledge the following limitations of the current study. Similar to any population-based registry, the SEER database has inherent limitations. Further details regarding the extent of lymph node dissection are included for only part of the time period analyzed, and there was no description regarding whether the lymph nodes were examined in an elective manner or as an intraoperative decision. Details regarding RT, such as breaks in treatment and receipt of high-dose versus low-dose treatment, also are not available. Socioeconomic data in the SEER database includes county-level rather than individual-level SES. These measures likely are correlated, although they may each represent independent risk factors in health outcomes. 31 In addition, information regarding chemotherapeutic agents or targeted therapy was not included in the SEER database, and therefore we were unable to account for the impact that this treatment modality may have had on outcomes. The effects of chemotherapy in patients with ATC have been described elsewhere-in a single-institution review, Rao et al found that patients receiving trimodality therapy (R0 or R1 surgical resection, chemotherapy, and external-beam RT) had longer OS compared with patients who received bimodal, nonsurgical therapy. 7 However, the survival difference noted may be due to selection bias: patients with advanced, unresectable disease are not considered to be surgical candidates, and therefore patients who receive trimodal therapy have less advanced disease and survival may be related to this fact. Small sample size also is a limitation of the current study. ATC is a rare yet aggressive malignancy, and the number of individuals affected is small. The use of national cancer registries to identify factors associated with treatment and survival sheds light on this rare disease. Last, SEER does not contain information regarding the time from diagnosis to treatment, which would be needed to measure the impact of immortal person-time bias on the current study results. Immortal person-time bias occurs when an outcome or intervention (ie, death in the current study) precedes an event (ie, the initiation of treatment), such that in the case of the current study, some patients may have received treatment because they were deemed to have a better prognosis at the time of diagnosis, compared with some patients whose poor prognosis at the time of diagnosis precluded them from treatment. Therefore, findings from the current study may not be causal.
Conclusions
In the current study, which to the best of our knowledge is the largest population-based cohort study of patients with ATC published to date, race/ethnicity, SES, and educational level were found to be associated with treatment and survival in these patients. Tumor size at the time of presentation and lymph node involvement did not appear to be associated with race/ethnicity. A majority of patients were treated with RT and thyroidectomy, and this was associated with race/ethnicity and educational level although not SES. The 5-year OS rate, although not the DSS rate, was found to be associated with race/ethnicity. Poverty was associated with both OS and DSS. Recognizing treatment and survival differences in patients with ATC may contribute to improvements in access to care for these patients, as well as more unbiased discussions of treatment in patients of all races/ethnicities, educational levels, and SES.
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